

LISTING OF CLAIMS

Claim 1 (previously presented): An isolated protein complex comprising two proteins, the protein complex selected from the group consisting of:

- (i) a complex of a first protein and a second protein;
- (ii) a complex of a fragment of said first protein and said second protein;
- (iii) a complex of said first protein and a fragment of said second protein; and
- (iv) a complex of a fragment of said first protein and a fragment of said second protein, wherein said first and second proteins of (i)-(iv) are selected from the group consisting of:
 - (a) said first protein is AKT1 or a homologue at least 90% identical thereto and said second protein is selected from the group consisting of FNTA, TPRD, KIAA0728, PPL and Golgin-84, or a homologue at least 90% identical thereto; and
 - (b) said first protein is AKT2 or a homologue at least 90% identical thereto and said second protein is selected from the group consisting of CLIC1, AKR7A2 and TPRD or a homologue at least 90% identical thereto.

Claim 46 (previously presented): A method for screening for drug candidates capable of modulating the interaction of the proteins of a protein complex, the protein complex selected from the group consisting of the protein complexes of claim 1, said method comprising:

- (i) combining the proteins of said protein complex in the presence of a drug to form a first complex;
- (ii) combining the proteins in the absence of said drug to form a second complex;
- (iii) measuring the amount of said first complex and said second complex; and
- (iv) comparing the amount of said first complex with the amount of said second complex, wherein if the amount of said first complex is greater than, or less than the amount of said second complex, then the drug is a drug candidate for modulating the interaction of the proteins of said protein complex.

Appl. No. 10/035,344

Appeal 2007-1142

Response dated July 11, 2007.

Reply to Decision On Appeal of May 11, 2007.

Claim 48 (previously presented): The method of claim 46, wherein said complex is measured by binding with an antibody specific for said protein complexes.

Claim 49 (previously presented): The method of claim 46, wherein if the amount of said first complex is greater than the amount of said second complex, then said drug is a drug candidate for promoting the interaction of said proteins.

Claim 50 (previously presented): The method of claim 46, wherein if the amount of said first complex is less than the amount of said second complex, then said drug is a drug candidate for inhibiting the interaction of said proteins.